Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib

Darapladib, a lipoprotein-associated phospholipase A2 (Lp-PLA(2)) inhibitor, failed to demonstrate efficacy for the primary endpoints in two large phase III cardiovascular outcomes trials, one in stable coronary heart disease patients (STABILITY) and one in acute coronary syndrome (SOLID-TIMI 52). N...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:PLoS One
Autors principals: Yeo, Astrid, Li, Li, Warren, Liling, Aponte, Jennifer, Fraser, Dana, King, Karen, Johansson, Kelley, Barnes, Allison, MacPhee, Colin, Davies, Richard, Chissoe, Stephanie, Tarka, Elizabeth, O’Donoghue, Michelle L., White, Harvey D., Wallentin, Lars, Waterworth, Dawn
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2017
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5533343/
https://ncbi.nlm.nih.gov/pubmed/28753643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0182115
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars